Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial

BACKGROUND: Anacetrapib is the only cholesteryl ester transfer protein inhibitor proven to reduce coronary heart disease (CHD). However, its effects on reverse cholesterol transport have not been fully elucidated. Macrophage cholesterol efflux (CEC), the initial step of reverse cholesterol transport...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Am Heart Assoc
Main Authors: Metzinger, Mark P., Saldanha, Suzanne, Gulati, Jaskeerat, Patel, Kershaw V., El‐Ghazali, Ayea, Deodhar, Sneha, Joshi, Parag H., Ayers, Colby, Rohatgi, Anand
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2020
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955402/
https://ncbi.nlm.nih.gov/pubmed/33263263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.018136
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍